Managed care pharmacy survey findings 2016

Managed care pharmacy survey findings 2016 Managed Healthcare Executive September 26, 2016 To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016. […]

VA Extending Hepatitis C Therapy

VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]

Telehealth Applications Patient Care

Telehealth Applications Patient Care Rita M. Marcoux, RPh, MBA; F. Randy Vogenberg, PhD, RPh, FASHP June 2016, Vol 7, No 5 – Employers’ Perspective – Value-Based Cancer Care The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using […]

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Big Data in Cancer Care: Limitations of Drug Claims

Big Data in Cancer Care: Limitations of Drug Claims VBCC – March 2016, Vol 7, No 2 – Employers’ Perspective Catherine E. Cooke, PharmD, BCPS F. Randy Vogenberg, PhD, RPh Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence; Principal, Institute for Integrated Healthcare Greenville, SC As one part of an ongoing macrotheme regarding big […]

Impact of Commercial Insurance in 2017

Clinical trial collaborations – an idea whose time has come

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Specialty Drug Spend Under the Medical Benefit

Continuation in rising costs of specialty drugs and maybe accelerate in next 1-2 years: Randy Vogenberg

Specialty Drug Spend Under the Medical Benefit — Biologic, biotechnology based, rare disease or high cost pharmaceuticals—collectively known as specialty drugs—can be covered under the pharmacy benefit, the medical benefit, or both depending on the plan sponsors’ benefit design required of the payor. On average, up to 50% of specialty drugs are covered under the […]

Oncology Care Marketing Increasing

Knowsource.com Announces Transition to Access Market Intelligence

Oncology care marketing increasing in the U.S. marketplace. However, continuing benefit coverage planning for 2017 are also topics that are receiving increasing attention—to include cancer care. Just as the new oncology product pipeline is providing new options or treatments for a wide variety of cancers, market stakeholders are continuing to adjust their daily practices around providing […]